Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Haleon PLC

Healthcare GB HLN

321.2GBX
0.30(0.09%)

Last update at 2026-06-03T15:37:00Z

Day Range

317.80324.05
LowHigh

52 Week Range

270.76411.39
LowHigh

Fundamentals

  • Previous Close 320.90
  • Market Cap32494.43M
  • Volume26800212
  • P/E Ratio20.24
  • Dividend Yield1.92%
  • EBITDA2743.00M
  • Revenue TTM11030.00M
  • Revenue Per Share TTM1.23
  • Gross Profit TTM 7144.00M
  • Diluted EPS TTM0.18

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 2152.00M 1910.00M 1628.00M 1618.00M 1636.00M
Minority interest -13.00000M -33.00000M -62.00000M - -49.00000M
Net income 1667.00M 1442.00M 1049.00M 1060.00M 1390.00M
Selling general administrative 4364.00M 4452.00M 2265.00M 4483.00M 4086.00M
Selling and marketing expenses - - 2023.00M - -
Gross profit 7144.00M 6824.00M 6747.00M 6577.00M 5950.00M
Reconciled depreciation 360.00M 324.00M 309.00M - 268.00M
Ebit 2475.00M 2487.00M 2483.00M 1825.00M 1638.00M
Ebitda 2835.00M 2683.00M 2674.00M 2163.00M 1951.00M
Depreciation and amortization 360.00M 196.00M 191.00M 338.00M 313.00M
Non operating income net other - - - - -
Operating income 2475.00M 2206.00M 1996.00M 1825.00M 1638.00M
Other operating expenses 8555.00M 9027.00M 9306.00M 9033.00M 7907.00M
Interest expense 340.00M 404.00M 414.00M 258.00M 12.00M
Tax provision 472.00M 435.00M 517.00M 499.00M 197.00M
Interest income 57.00M 65.00M 34.00M 5.00M 34.00M
Net interest income -305.00000M -339.00000M -368.00000M - -2.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 472.00M 435.00M 517.00M 499.00M 197.00M
Total revenue 11030.00M 11233.00M 11302.00M 10858.00M 9545.00M
Total operating expenses 4669.00M 4618.00M 4751.00M 4752.00M 4312.00M
Cost of revenue 3886.00M 4409.00M 4555.00M 4281.00M 3595.00M
Total other income expense net -323.00000M -296.00000M -368.00000M -207.00000M -2.00000M
Discontinued operations - - - - -
Net income from continuing ops 1680.00M 1475.00M 1111.00M - 1439.00M
Net income applicable to common shares - - - 1060.00M 1390.00M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 32630.00M 34315.00M 34055.00M 34815.00M 34451.00M
Intangible assets 17486.00M 18009.00M 18538.00M 20040.00M 18949.00M
Earning assets - - - - -
Other current assets 78.00M 429.00M 1014.00M - 61.00M
Total liab 16146.00M 18091.00M 17326.00M 18358.00M 7971.00M
Total stockholder equity 16425.00M 16166.00M 16606.00M 16331.00M 26355.00M
Deferred long term liab - - - - -
Other current liab 367.00M 2066.00M 1820.00M 312.00M 1954.00M
Common stock 90.00M 91.00M 92.00M 92.00M 1.00M
Capital stock 90.00M 91.00M 92.00M - 1.00M
Retained earnings 16160.00M 27272.00M 27474.00M 26730.00M 37986.00M
Other liab - - - - -
Good will 8127.00M 8202.00M 8317.00M 8396.00M 8246.00M
Other assets - - - - -
Cash 1324.00M 2195.00M 1044.00M 684.00M 414.00M
Cash and equivalents - - - - -
Total current liabilities 4933.00M 5812.00M 4640.00M 4370.00M 4238.00M
Current deferred revenue - - 21.00M - 11.00M
Net debt 7285.00M 7907.00M 8412.00M 9756.00M 577.00M
Short term debt 836.00M 1487.00M 656.00M 437.00M 904.00M
Short long term debt 788.00M 1437.00M 656.00M - 874.00M
Short long term debt total 8609.00M 10102.00M 9456.00M 10440.00M 991.00M
Other stockholder equity -161.00000M -115.00000M -10960.00000M -10491.00000M -
Property plant equipment - - - - -
Total current assets 4550.00M 5718.00M 4818.00M 4059.00M 5251.00M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - -36.00000M - 1.00M
Net receivables 2123.00M 1904.00M 1352.00M - 3825.00M
Long term debt 7663.00M 8542.00M 8800.00M - -
Inventory 1025.00M 1190.00M 1408.00M 1348.00M 951.00M
Accounts payable 3730.00M 1973.00M 1855.00M 3621.00M 1369.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 336.00M -11081.00000M -10960.00000M - -11632.00000M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 105.00M 107.00M 150.00M 132.00M 8.00M
Deferred long term asset charges - - - - -
Non current assets total 28080.00M 28597.00M 29237.00M 30756.00M 29200.00M
Capital lease obligations 133.00M 123.00M 137.00M - 117.00M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -6.00000M 528.00M -134.00000M - -33.00000M
Change to liabilities - - - - -
Total cashflows from investing activities -580.00000M 528.00M -134.00000M - -
Net borrowings -1306.00000M 652.00M -553.00000M - -
Total cash from financing activities -2612.00000M -1537.00000M -1568.00000M 6911.00M -1236.00000M
Change to operating activities - - - - -
Net income 1667.00M 1475.00M 1111.00M 1119.00M 1439.00M
Change in cash -926.00000M 1213.00M 383.00M 205.00M 82.00M
Begin period cash flow 2250.00M 994.00M 611.00M 406.00M 323.00M
End period cash flow 1324.00M 2207.00M 994.00M 611.00M 405.00M
Total cash from operating activities 2337.00M 2301.00M 2100.00M 2063.00M 1356.00M
Issuance of capital stock - - - - -
Depreciation 360.00M 324.00M 309.00M 287.00M 268.00M
Other cashflows from investing activities - 332.00M 171.00M - -
Dividends paid 612.00M 570.00M 388.00M 2682.00M 1148.00M
Change to inventory 133.00M 216.00M -131.00000M -292.00000M -17.00000M
Change to account receivables -65.00000M -312.00000M 38.00M - 14.00M
Sale purchase of stock -654.00000M -619.00000M -38.00000M - -
Other cashflows from financing activities -40.00000M -1000.00000M -589.00000M 11111.00M -88.00000M
Change to netincome - - - - -
Capital expenditures 322.00M 318.00M 336.00M 328.00M 298.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 256.00M 206.00M -107.00000M 181.00M -152.00000M
Stock based compensation 86.00M 102.00M 88.00M - -376.00000M
Other non cash items 54.00M 194.00M 699.00M 476.00M -20.00000M
Free cash flow 2015.00M 1983.00M 1764.00M 1735.00M 1058.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
HLN
Haleon PLC		 0.30 0.09% 321.20 20.24 18.94 2.95 2.02 3.68 14.19
HIK
Hikma Pharmaceuticals PLC		 -5.0 0.35% 1416.00 9.73 9.03 0.85 1.45 1.53 6.07
HCM
HUTCHMED China Ltd		 1.00 0.57% 175.00 5.38 19.30 3.37 2.02 2.25 2.40
AGY
Allergy Therapeutics		 0.20 2.35% 8.70 - 106.38 11.72 159.47 12.12 -4.1496
ANCR
Animalcare Group Plc		 - -% 331.50 61.50 16.92 2.09 1.43 2.13 14.48

Reports Covered

Stock Research & News

View All

Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Haleon PLC

The Heights, Weybridge, United Kingdom, KT13 0NY

Key Executives

Name Title Year Born
Mr. Brian McNamara CEO & Exec. Director 1967
Mr. Tobias Hestler CFO & Exec. Director 1972
Ms. Amy Landucci Head of Digital and Technology NA
Mr. Bjarne Philip Tellmann Gen. Counsel 1967
Ms. Tamara Rogers Chief Marketing Officer 1969
Ms. Mairead Nayager Chief HR Officer 1975
Mr. Bart Derde Head of Quality and Supply Chain 1969
Mr. Filippo Lanzi Head of EMEA & LatAm NA
Ms. Teri Lyng Head of Transformation & Sustainability 1962
Ms. Jooyong Lee Head of Strategy and Office of the CEO 1977

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions